PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 35489781-7 2022 Additionally, the EP50 value for hyperactivity induced by fentanyl/naltrexone mixtures indicated that opioid-induced hyperactivity in mice has a relatively high efficacy requirement in comparison to some other MOR agonist effects, and in particular is higher than the efficacy requirement for thermal antinociception in mice or fentanyl discrimination in rats. Naltrexone 67-77 opioid receptor, mu 1 Mus musculus 210-213 26877219-10 2016 Moreover, late stage treatment with MS and naltrexone inhibited the effect of MS on neuronal differentiation, suggesting that MS treatment interferes with differentiation via MOR activation. Naltrexone 43-53 opioid receptor, mu 1 Mus musculus 175-178 34183434-2 2021 The mu-opioid receptor (MOPr) partial agonist buprenorphine, alone or in combination with naltrexone, has been shown to reduce cocaine positive urine tests and cocaine seeking in rodents. Naltrexone 90-100 opioid receptor, mu 1 Mus musculus 4-22 34183434-2 2021 The mu-opioid receptor (MOPr) partial agonist buprenorphine, alone or in combination with naltrexone, has been shown to reduce cocaine positive urine tests and cocaine seeking in rodents. Naltrexone 90-100 opioid receptor, mu 1 Mus musculus 24-28 34071603-6 2021 Antinociceptive effects of KGNOP1 were reversed by naltrexone and SB-612111, indicating the involvement of both MOR and NOP receptor agonism. Naltrexone 51-61 opioid receptor, mu 1 Mus musculus 112-115 34018697-0 2021 Naltrexone is neuroprotective against traumatic brain injury in mu opioid receptor knockout mice. Naltrexone 0-10 opioid receptor, mu 1 Mus musculus 64-82 34018697-13 2021 CONCLUSION: Naltrexone reduced TBI-mediated neurodegeneration and inflammation in MOR WT and KO mice. Naltrexone 12-22 opioid receptor, mu 1 Mus musculus 82-85 34018697-14 2021 The protective effect of naltrexone involves non-MOR and MOR mechanisms. Naltrexone 25-35 opioid receptor, mu 1 Mus musculus 49-52 34018697-14 2021 The protective effect of naltrexone involves non-MOR and MOR mechanisms. Naltrexone 25-35 opioid receptor, mu 1 Mus musculus 57-60 28291693-5 2017 Since naltrexone binds with high affinity to both MOR and DOR, it was selected as the platform for development of novel ligands capable of delivering a cytotoxic payload to non-small cell lung cancer (NSCLC). Naltrexone 6-16 opioid receptor, mu 1 Mus musculus 50-53 33073190-1 2020 IBNtxA (3-iodobenzoyl naltrexamine) is a novel mu-opioid receptor (MOR) agonist which is structurally related to the MOR antagonist naltrexone. Naltrexone 132-142 opioid receptor, mu 1 Mus musculus 47-65 33073190-1 2020 IBNtxA (3-iodobenzoyl naltrexamine) is a novel mu-opioid receptor (MOR) agonist which is structurally related to the MOR antagonist naltrexone. Naltrexone 132-142 opioid receptor, mu 1 Mus musculus 67-70 33073190-1 2020 IBNtxA (3-iodobenzoyl naltrexamine) is a novel mu-opioid receptor (MOR) agonist which is structurally related to the MOR antagonist naltrexone. Naltrexone 132-142 opioid receptor, mu 1 Mus musculus 117-120 31991139-7 2020 Conversely, the effects of NTX were blocked only in Oprm1-/- mice. Naltrexone 27-30 opioid receptor, mu 1 Mus musculus 52-57 30723430-15 2018 Furthermore, co-treatment with the MOR antagonist naltrexone blocked morphine"s anti-nociception in animals given either EtOH or saline. Naltrexone 50-60 opioid receptor, mu 1 Mus musculus 35-38 30048644-2 2018 Several preclinical and clinical studies have demonstrated that the mu opioid receptor (MOPr) antagonist/kappa opioid receptor (KOPr) partial agonist naltrexone (NTX) reduces the subjective effects and self-administration of cocaine. Naltrexone 150-160 opioid receptor, mu 1 Mus musculus 68-86 30048644-2 2018 Several preclinical and clinical studies have demonstrated that the mu opioid receptor (MOPr) antagonist/kappa opioid receptor (KOPr) partial agonist naltrexone (NTX) reduces the subjective effects and self-administration of cocaine. Naltrexone 150-160 opioid receptor, mu 1 Mus musculus 88-92 30048644-2 2018 Several preclinical and clinical studies have demonstrated that the mu opioid receptor (MOPr) antagonist/kappa opioid receptor (KOPr) partial agonist naltrexone (NTX) reduces the subjective effects and self-administration of cocaine. Naltrexone 162-165 opioid receptor, mu 1 Mus musculus 68-86 30048644-2 2018 Several preclinical and clinical studies have demonstrated that the mu opioid receptor (MOPr) antagonist/kappa opioid receptor (KOPr) partial agonist naltrexone (NTX) reduces the subjective effects and self-administration of cocaine. Naltrexone 162-165 opioid receptor, mu 1 Mus musculus 88-92 30048644-5 2018 In vivo characterization of these NTX and NMF doses were performed to examine their effectiveness at MOPr and KOPr. Naltrexone 34-37 opioid receptor, mu 1 Mus musculus 101-105 30048644-9 2018 High dose NTX and both NMF doses fully blocked MOPr agonist morphine-induced thermal analgesia as well as KOPr agonist U50,488H-induced locomotor discoordination. Naltrexone 10-13 opioid receptor, mu 1 Mus musculus 47-51 30048644-10 2018 However, low dose NTX fully blocked morphine analgesia but not U50,488H locomotor discoordination suggesting that low dose NTX is effective at MOPr but not KOPr. Naltrexone 123-126 opioid receptor, mu 1 Mus musculus 143-147 29105118-3 2018 In this study, we investigated whether SSR149415 alone or in combination with the mu-opioid receptor (MOP-r) antagonist naltrexone (NTN) would alter excessive alcohol drinking in mice. Naltrexone 120-130 opioid receptor, mu 1 Mus musculus 102-107 28291693-8 2017 Naltrexone and naltrindole were used as competition for MOR and DOR respectively during the binding affinity studies. Naltrexone 0-10 opioid receptor, mu 1 Mus musculus 56-59 24866991-1 2015 BACKGROUND AND PURPOSE: Opioid antagonists, such as naloxone and naltrexone, exhibit agonistic properties at the mutated mu receptor, MOR-S196ACSTA. Naltrexone 65-75 opioid receptor, mu 1 Mus musculus 134-137 27818236-6 2017 Both cyprodime and naltrexone significantly reduced approach latency at doses experimentally proven to antagonize the MOR. Naltrexone 19-29 opioid receptor, mu 1 Mus musculus 118-121 26049209-4 2016 To establish the in vivo role of GluA1-Serine 845 (S845) phosphorylation on the behavioral effect induced by inhibition of the endogenous mu-opioid receptor (MOR) by naltrexone, MOR knockout, and GluA1-S845A mutant (in which Ser(845) was mutated to Ala) mice were tested in a water maze after chronic naltrexone administration. Naltrexone 166-176 opioid receptor, mu 1 Mus musculus 138-156 26049209-4 2016 To establish the in vivo role of GluA1-Serine 845 (S845) phosphorylation on the behavioral effect induced by inhibition of the endogenous mu-opioid receptor (MOR) by naltrexone, MOR knockout, and GluA1-S845A mutant (in which Ser(845) was mutated to Ala) mice were tested in a water maze after chronic naltrexone administration. Naltrexone 166-176 opioid receptor, mu 1 Mus musculus 158-161 25442002-1 2015 BACKGROUND: It has been proposed that therapeutic responses to naltrexone in alcoholism are moderated by variation at the mu-opioid receptor gene locus (OPRM1). Naltrexone 63-73 opioid receptor, mu 1 Mus musculus 153-158 24866991-8 2015 KEY RESULTS: Anti-allodynic effects, as measured by von Frey test, increased after naltrexone or morphine treatment in mice transfected with LV-MOR-S196ACSTA in the spinal cord. Naltrexone 83-93 opioid receptor, mu 1 Mus musculus 144-147 24866991-10 2015 CONCLUSIONS AND IMPLICATIONS: Systemic injection of naltrexone after the expression of a mutant mu opioid receptor, MOR-S196ACSTA, in the spinal cord may have therapeutic potential for chronic neuropathic pain, without the development of dependence or addiction. Naltrexone 52-62 opioid receptor, mu 1 Mus musculus 116-119 25017386-5 2014 The opioid antagonists naltrexone, naltrindole and nor-binaltorphimine, suggests that the synergism of morphine combinations are due to the activation of MOR subtypes with partially contribution of DOR and KOR, however fentanyl and methadone combinations are partially due to the activation of MOR and DOR subtypes and KOR lack of participation. Naltrexone 23-33 opioid receptor, mu 1 Mus musculus 154-157 17845912-10 2007 In in vitro studies, HS-731 and DAMGO, but not morphine showed high intrinsic efficacy, naltrexone-sensitive agonist effect at MOR of the rat vas deferens. Naltrexone 88-98 opioid receptor, mu 1 Mus musculus 127-130 24144240-0 2013 Design, synthesis, and biological evaluation of 14-heteroaromatic-substituted naltrexone derivatives: pharmacological profile switch from mu opioid receptor selectivity to mu/kappa opioid receptor dual selectivity. Naltrexone 78-88 opioid receptor, mu 1 Mus musculus 138-156 24144240-1 2013 On the basis of a mu opioid receptor (MOR) homology model and the isosterism concept, three generations of 14-heteroaromatically substituted naltrexone derivatives were designed, synthesized, and evaluated as potential MOR-selective ligands. Naltrexone 141-151 opioid receptor, mu 1 Mus musculus 18-36 24144240-1 2013 On the basis of a mu opioid receptor (MOR) homology model and the isosterism concept, three generations of 14-heteroaromatically substituted naltrexone derivatives were designed, synthesized, and evaluated as potential MOR-selective ligands. Naltrexone 141-151 opioid receptor, mu 1 Mus musculus 38-41 24144240-1 2013 On the basis of a mu opioid receptor (MOR) homology model and the isosterism concept, three generations of 14-heteroaromatically substituted naltrexone derivatives were designed, synthesized, and evaluated as potential MOR-selective ligands. Naltrexone 141-151 opioid receptor, mu 1 Mus musculus 219-222 22240038-7 2012 In the same cells, the mu opioid receptor (MOR) antagonist Naltrexone increases TLR4 levels, thus suggesting a role of the endogenous opioid system in TLR4 regulation. Naltrexone 59-69 opioid receptor, mu 1 Mus musculus 23-41 22240038-7 2012 In the same cells, the mu opioid receptor (MOR) antagonist Naltrexone increases TLR4 levels, thus suggesting a role of the endogenous opioid system in TLR4 regulation. Naltrexone 59-69 opioid receptor, mu 1 Mus musculus 43-46 15219707-7 2004 Thus, the results of the present study revealed that the effects of these naltrexone pretreatments on ethanol-induced locomotion are similar to the previously described changes on MOR activity. Naltrexone 74-84 opioid receptor, mu 1 Mus musculus 180-183 15219707-8 2004 Moreover, the same (acute and chronic) naltrexone pretreatments produced similar changes on the locomotion of mice after a challenge with morphine (a MOR agonist), but not after tert-butanol (an alcohol which does not release beta-endorphins) administration. Naltrexone 39-49 opioid receptor, mu 1 Mus musculus 150-153 14600246-6 2004 Moreover, naloxone and naltrexone stimulated adenylyl cyclase activity in striatum homogenates only after morphine pretreatment, by reversing the inhibitory effects of basal MOR activity. Naltrexone 23-33 opioid receptor, mu 1 Mus musculus 174-177 12957235-2 2003 In previous studies, naltrexone treatment produced an increase in muOR density accompanied by decreases in GRK-2 and DYN-2 protein abundance. Naltrexone 21-31 opioid receptor, mu 1 Mus musculus 66-70